KRAS2 mutations in codon 12 have been detected in about 80% of pancreatic cancers. The aim of this study was to evaluate the value of KRAS2 mutations detection in circulating deoxyribo nucleic acid to differentiate pancreatic cancer from chronic pancreatitis. Circulating deoxyribo nucleic acid was isolated from serum in 47 patients with histologically proven pancreatic adenocarcinomas (26 males, median age 65 years) and 31 controls with chronic pancreatitis (26 males, median age 48 years). Mutations at codon 12 of KRAS2 gene were searched for using polymerase chain reaction and allele specific amplification. Serum carbohydrate antigen 19.9 levels were also determined. KRAS2 mutations were found in 22 patients (47%) with pancreatic cancer and in four controls with chronic pancreatitis (13%) (P50.002). None of the latter developed a pancreatic cancer within the 36 months of median follow-up. The sensitivity, specificity, positive and negative predictive values of serum serum KRAS2 mutations for the diagnosis of pancreatic cancer were 47, 87, 85 and 52%, respectively. KRAS2 mutations were not related to age, gender, smoking habit, tumour stage, or survival. Among the 26 patients with normal or non-contributive (due to cholestasis) serum carbohydrate antigen 19.9 levels, 14 (54%) had KRAS2 mutations. The combination of KRAS2 and carbohydrate antigen 19.9 gave a sensitivity, specificity, positive and negative predictive values for the diagnosis of pancreatic cancer of 98, 77, 87 and 96%, respectively. Detection of KRAS2 mutations in circulating deoxyribo nucleic acid has a low sensitivity but a specificity about 90% for the diagnosis of pancreatic cancer. It seems particularly useful when serum carbohydrate antigen 19.9 levels are normal or inconclusive. A combined normal serum carbohydrate antigen 19.9 and absence of circulating KRAS2 mutations makes the diagnosis of pancreatic cancer extremely unlikely.
Five-year survival in patients with pancreatic adenocarcinomas is less than 5%, partly due to advanced disease at diagnosis. The differentiation between pancreatic cancer and chronic pancreatitis can be particularly difficult leading to inappropriate treatment. Serum carbohydrate antigen 19.9 (Ca 19.9) levels are elevated in 80% of pancreatic cancer patients, but can also be increased in 20% of patients with chronic pancreatitis (Satake and Takeuchi, 1994; Nouts et al, 1998) . Moreover, pancreatic inflammation, as observed in chronic pancreatitis, can be mistaken on imaging as cancer and inversely. An accurate and non-invasive test to differentiate pancreatic cancer from chronic pancreatitis would be extremely helpful.
Previous studies have reported KRAS2 gene mutations (almost always confined to codon 12) in 75 to 95% of exocrine pancreatic cancer (Caldas and Kern, 1995) . KRAS2 mutations provoke activation of nuclear transcriptor factors, resulting in cellular proliferation and also in tumour angiogenesis as reported recently (Banerjee et al, 2000; Ikeda et al, 2001) . Detection of KRAS2 mutations were first reported in surgically removed pancreatic tumoural tissue or at autopsy (Almoguera et al, 1988; Tada et al, 1991) . Thereafter mutations were discovered in 63 to 83% of samples of pure pancreatic juice or main pancreatic duct brushing obtained during endoscopic retrograde pancreatography (Iguchi et al, 1996; Kondo et al, 1997; Tada et al, 1998; Van Laethem et al, 1998; Okai et al, 1999; Watanabe et al, 1999; Ha et al, 2001; Pugliese et al, 2001; Seki et al, 2001) or at fine-needle tumour aspiration (Pabst et al, 1999; Puig et al, 2000) , and in 20 to 54% of stools (Caldas et al, 1994; Wenger et al, 1999) from patients with pancreatic cancer. Circulating deoxyribo nucleic acid (DNA) was first detected in serum or plasma of normal subjects in 1975 (Steinman, 1975) . Since then, mutations in the KRAS2 gene have been detected in the plasma of patients with colorectal, lung and haematological cancers (Anker et al, 1997) . To date, few studies have reported KRAS2 mutations in circulating DNA in patients with pancreatic cancer with a wide spectrum of sensitivity (27 to 81%) (Sorenson et al, 1994; Mulcahy et al, 1998; Yamada et al, 1998; Castells et al, 1999; Porta et al, 1999; Theodor et al, 2000) . The aim of our study was to evaluate the value of KRAS2 mutation detection in circulating DNA in a large series of patients to differentiate pancreatic adenocarcinoma from chronic pancreatitis.
PATIENTS AND METHODS

Selection and outcome of patients
Between January 1995 and 1999, 47 patients (26 males and 21 females, median age 65 years (range 39 -84)) with pancreatic ductal adenocarcinoma were included in the study. In all of them, diagnosis was confirmed by pathological examination of pancreatic tumour obtained by fine needle aspiration during endoscopic ultrasonography (n=42) or operative procedure (n=5). Tumour staging was established by abdominal computed tomography, endoscopic ultrasonography or operative findings: stage I (n=5, 11%), stage II or III (n=19, 40%) and stage IV (n=23, 49%) according to the TNM classification (UICC, 1997). Five patients underwent surgical resection, 32 patients received systemic chemotherapy and/or radiotherapy and 10 symptomatic treatment. Median follow-up was 6 months (range 1 -24). At the end of the study, all but four patients with pancreatic cancer were dead.
Control group
A control group was recruited during the same time in the same centre and included 31 patients with chronic pancreatitis (26 men and five women, median age 48 years (range 20 -64)). Diagnosis of chronic pancreatitis relied upon the presence of pancreatic calcifications and/or irregularity of pancreatic ducts, according to Cambridge Classification (Axon et al, 1984) on computed tomography scan and endoscopic retrograde pancreatography, respectively. Etiology of chronic pancreatitis was alcoholic in 30 patients and idiopathic in one patient. No case of pancreatic cancer occurred during the 36-month follow-up in these 31 patients.
DNA extraction and quantification
Peripheral venous blood samples were collected after informed consent in patients and controls. Blood samples were centrifuged, serum was removed and stored at 7208C until use. DNA was extracted from serum by using the QIAmp Blood Kit (Qiagen, Courtaboeuf, France) according to the blood and body fluid protocol recommended by the manufacturer. Two millilitres of serum were used, and a DNA elution volume of 50 ml was obtained by extraction. The DNA elution was then concentrated to a final volume of 15 ml.
Quantification of serum DNA was performed for all samples using a volume of 3 ml of DNA elution obtained after Qiagen extraction by fluorescence emission after intercalation of Hoeschst dye. The fluorescence was read by DyNA Quantô 200 fluorimeter, using the cuve and capillary DyDNA Capillary Cuvette Adaptor Kit (Pharmacia Biotech, Orsay, France). The threshold of DNA detection established by the manufacturer is 2 ng ml 71 , which corresponds to 100 ng ml 71 serum in our extraction protocol (Coulet et al, 2000) .
Detection of KRAS2 gene mutations
Only G12D mutations in codon 12 of the KRAS2 gene were searched for using allele-specific amplification, with the following primers: 5'-CTTGTGGTAGTTGGAGCTAA-3', 5'-AATGGTCCT-GCACCAGTAATATG-3'. Amplifications were performed with 0.3 mM of each primers, 200 mM of each deoxynucleotide triphosphate (dNTP), 1.5 mM of MgCl 2 , 0.025 units per ml of AmpliTaq Gold polymerase Cetus (Perkin Elmer), 2.5 ml or 5 ml of 106 buffer, 5 ml of the concentrated DNA elution was used as template in a 50 ml volume reaction. Polymerase chain reaction (PCR) with serum DNA was performed 10 min at 948C, followed by 60 cycles of 948C for 30 s, 618C for 30 s, 728C for 1 min and a final extension of 10 min at 728C. Controls without DNA and positive controls were performed for each set of PCR reactions. PCR products were separated by electrophoresis in a 6% acrylamide gel and stained with ethidium bromide.
Serum Ca 19.9 dosage
The serum value of Ca 19.9 was measured with a commercial solidphase double-antibody sandwich immunoassay (Roche Laboratories, Basel, Switzerland). The upper limit of normal value was 37 UI ml 71 . All patients and controls also underwent biochemical liver tests. Cholestasis was defined by alkaline phosphatase levels above twice the normal value.
Statistical analysis
For each marker (serum KRAS2 mutations and Ca 19.9), sensitivity, specificity, positive and negative predictive values were calculated. Thereafter, the combination of both markers (i.e., one and/or the other positive) was studied. The chi-squared test was used to compare the occurrence of KRAS2 mutations. Differences were considered significant when P50.05.
RESULTS
Circulating DNA quantification
Adequate DNA was extracted from the serum in sufficient quantities for analysis in all patients and controls. All patients but one had a serum DNA concentration higher than the threshold of detection of 100 ng ml 71 . The mean concentrations of DNA extracted from serum of patients with pancreatic cancer and chronic pancreatitis were 730+90 ng ml 71 and 560+93 ng ml 71 , respectively (P=0.19).
KRAS2 mutations in circulating DNA
KRAS2 mutations were identified in the serum of 22 patients (47%) with pancreatic adenocarcinoma and in four patients (13%) with chronic pancreatitis (P50.002). The sensitivity, specificity, positive and negative predictive values of serum KRAS2 mutations for the diagnosis of pancreatic cancer were 47, 87, 85 and 52%, respectively. There were no statistically significant differences in age, gender, smoking, tumour stage and survival, according to presence or absence of plasma KRAS2 mutations.
Among patients with chronic pancreatitis, no cancer occurred after a mean follow-up of 36 months (range 13 -64), even in those with positive KRAS2 mutations (with follow-up of 40 months, range 20 -61), assessed by clinical observation and abdominal computed tomography scan.
Serum Ca 19.9 levels
The sensitivity, specificity, positive and negative predictive values of abnormal Ca 19.9 levels for the diagnosis of pancreatic cancer were 91, 87, 91 and 87%, respectively (Table 1) . Serum Ca 19.9 levels were normal or non interpretable due to cholestasis in 26 patients. Among them, 14 (54%) patients had serum KRAS2 mutations. Combination of both tests increased sensitivity to 98% with a negative predictive value of 96% for the diagnosis of pancreatic cancer (Table 1) .
DISCUSSION
In the present study, only the most frequent KRAS2 gene mutation G12D (aspartic acid) observed in pancreatic cancer (Iguchi et al, 1996; Tada et al, 1998; Castells et al, 1999; was analysed in the serum of patients and controls, in
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Our study underlines the high feasibility of KRAS2 mutations analysis, as circulating DNA was obtained in sufficient quantities in all patients. Mean serum DNA concentration were 730 ng ml 71 , which is comparable to that observed in the series of Mulcahy et al (1998) .
In the present study, detection of KRAS2 mutations in circulating DNA had a low sensitivity but a high specificity for the diagnosis of pancreatic cancer. The sensitivity (47%) was in agreement with previous studies (27 to 81%) (Mulcahy et al, 1998; Yamada et al, 1998; Castells et al, 1999; Porta et al, 1999; Theodor et al, 2000; Zambon et al, 2000) , although the search for five other possible KRAS2 mutations in codon 12 was not performed. Higher KRAS2 mutation prevalences have been reported in pancreatic or duodenal juice (63 to 87%), due probably to higher DNA tumour content in pancreatic juice as compared to plasma (Wilentz et al, 1998; Van Laethem et al, 1998; Watanabe et al, 1999) . Use of samples of pancreatic juice however requires invasive procedures (fine-needle aspiration during endoscopic ultrasonography or endoscopic retrograde pancreatography). Three studies have reported a higher specificity of serum KRAS2 mutations compared to the current study (100 vs 87%), but their control groups included few patients and essentially healthy subjects (Mulcahy et al, 1998; Porta et al, 1999; Theodor et al, 2000) . Since KRAS2 mutations have been reported in pancreatic tissue or juice from 6 -42% of patients with chronic pancreatitis (Furuya et al, 1997; Mulligan et al, 1999; Lüttges et al, 2000; Ha et al, 2001) , and knowing that a part of this mutated DNA can be released into circulation (Yamada et al, 1998) , the control group should include patients with chronic pancreatitis. In the series published by Castells et al (1999) with the largest control group (including patients with chronic pancreatitis), specificity was comparable (94%) to the present study, and increased in the presence of a pancreatic mass. The accuracy of serum KRAS2 mutation detection in the differential diagnosis between pancreatic cancer and chronic pancreatitis may be improved by performing quantitative PCR measurement of mutated DNA, in order to discriminate patients with unspecific low levels of mutated DNA (as supposed in chronic pancreatitis) from patients with high levels (pancreatic cancer), as suggested in pancreatic juice analysis by Tada et al (1998) .
Serum Ca 19.9 is widely used for pancreatic cancer diagnosis with a sensitivity of 80% (Satake and Takeuchi, 1994) . This marker is not informative in 5% of population who cannot express serum Ca 19.9 due to Lewis a negative status (Narimatsu et al, 1996) . However, serum Ca 19.9 lacks specificity (70 to 80%): it can be increased in cholestasis, diabetes mellitus or chronic pancreatitis (Nouts et al, 1998) . In the present study, serum Ca 19.9 had very good specificity (87%), similar to that of serum KRAS2 mutations. Combination of both tests could be useful to assess cancer diagnosis in patients with normal or non contributive Ca 19.9 due to cholestasis or negative Lewis a antigen status, and to exclude cancer diagnosis when both tests are negative (predictive negative value of 96%).
In the present study, the presence of KRAS2 mutations in serum was not correlated to age, gender and smoking habit. It was neither correlated to tumour stage since mutations were detected in plasma of patients with non metastatic tumours, which supports the hypothesis that KRAS2 mutations are early events in pancreatic carcinogenesis (Jimenez et al, 1999) . Two studies in the literature are in agreement with this result (Yamada et al, 1998; Theodor et al, 2000) , but another one found a statistically significant relation between circulating DNA KRAS2 mutations and poor prognosis (Castells et al, 1999) . Yamada et al (1998) have reported disappearance of detectable mutation in plasma after tumoural resection or radio-chemotherapy in six of nine patients, suggesting KRAS2 mutations may be used as a tumour relapse marker.
Screening for malignancy in patients with chronic pancreatitis is a difficult challenge. Patients with chronic pancreatitis have an increased risk of pancreatic cancer, estimated at 1.8% at 10 years and 4% at 20 years (Lowenfels et al, 1993) . Three studies have evaluated occurrence of pancreatic cancer in patients with chronic pancreatitis with respect to KRAS2 mutations in pancreatic juice: only one found an increase in pancreatic cancer in patients with KRAS2 mutations with methodological limitations (few cases, early diagnosis of cancer after inclusion) (Furuya et al, 1997; Lohr et al, 2001; Queneau et al, 2001 ). To our knowledge, no study focused on the incidence of pancreatic cancer in patients with chronic pancreatitis according to serum KRAS2 mutations. In the present study, follow-up was too short to demonstrate an increased risk of cancer in patients with chronic pancreatitis and serum KRAS2 mutations.
In conclusion, although detection of plasma KRAS2 mutations in circulating DNA is not a definitive argument for malignancy, it could contribute to cancer diagnosis. This test seems particularly interesting in patients with normal or inconclusive Ca 19.9 levels due to cholestasis or Lewis a negative status. In patients with normal serum Ca 19.9 levels and no KRAS2 mutation, the diagnosis of pancreatic cancer can be excluded with almost certainty. 
